BrainsWay Announces Strategic Investment in Radial Health, Inc.

Rhea-AI Summary

BrainsWay (NASDAQ & TASE: BWAY) announced a $3 million strategic minority equity investment in Radial Health, a management services organization supporting a nationwide network of Brain Medicine clinics, as part of Radial's previously announced Series A financing round.

According to BrainsWay, Radial develops clinical infrastructure, reimbursement tools, and an AI-guided decision support platform to support noninvasive Brain Medicine treatments such as Deep TMS and other therapies. The company said this investment aligns with its strategy to take minority stakes in high-performing mental health provider networks to broaden awareness and access to advanced, evidence-based psychiatric care.

Positive

• $3 million minority equity investment in Radial Health’s Series A financing
• Supports stated strategy to secure minority stakes in mental health provider networks
• Partnership with a Brain Medicine platform focused on Deep TMS and noninvasive therapies

Negative

• None.

News Market Reaction – BWAY

+4.90% 3.0x vol

8 alerts

+4.90% Session close to close

+3.6% Peak in 3 hr 53 min

$631.24M Market Cap

3.0x Rel. Volume

In the Jul 20 session, BWAY gained 4.90%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

BrainsWay's comparable minority-stake announcements were followed by -0.34% and -1% 24-hour reaction...

Analysis

BrainsWay's comparable minority-stake announcements were followed by -0.34% and -1% 24-hour reactions. That record contextualizes this $3 million investment, while recent insider net selling remains a risk factor.

Key Figures

Investment: $3 million

1 metrics

Investment $3 million Minority equity investment in Radial's Series A financing

Historical Context

5 past events · Latest: Jul 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 16	Minority-stake investment	Positive	-0.3%	Sound Minds investment supported expansion of access to interventional psychiatric care.
Jun 29	Clinical data presentation	Positive	+4.8%	Real-world Deep TMS study reported response and remission results in comorbid patients.
Jun 22	Coverage expansion update	Positive	-3.4%	Expanded payer coverage increased access to accelerated TMS approaches for covered lives.
Jun 09	Clinical data presentation	Positive	-0.9%	SWIFT data showed one-year remission and reduced severe functional impairment among treated patients.
May 18	Minority-stake investment	Positive	-1.0%	Hopemark investment expanded BrainsWay's provider-partnership strategy for advanced psychiatric treatments.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Comparable minority-stake announcements were followed by negative 24-hour reactions, while clinical and coverage updates produced mixed outcomes.

Key Terms

minority equity investment, management services organization, series a financing, m&a

4 terms

minority equity investment financial

"announced a $3 million minority equity investment in Radial"

Minority equity investment is the purchase of a less-than-50% ownership stake in a company, giving the investor economic rights to profits and losses but not outright control of decisions. It matters to investors because it shapes their level of influence, exposure to company performance, voting power, and potential for returns or dilution—similar to owning a slice of a pie without being able to call the kitchen’s shots.

management services organization technical

"Radial Health, Inc., a management services organization supporting"

A management services organization (MSO) is a company that handles non-clinical, back-office functions for healthcare practices or other businesses—things like billing, staffing, IT, compliance and purchasing—so the licensed professionals can focus on core services. For investors, an MSO can improve efficiency, reduce costs and enable faster growth, but it also creates dependencies and regulatory or operational risks that can affect profitability and valuation.

series a financing financial

"as part of Radial's previously-announced Series A financing"

A Series A financing is an early formal round of investment in a growing private company where outside investors provide significant capital in exchange for a stake in the business. It matters to investors because it helps set the company's market value, shows that professional backers believe the business can scale, and determines how much ownership current holders keep—similar to bringing in a partner to fund and accelerate a first big expansion.

m&a financial

"support Radial’s exploration of various M&A opportunities"

M&A, short for mergers and acquisitions, involves one company combining with or purchasing another company to grow, streamline operations, or gain competitive advantages. For investors, M&A activity can signal potential for increased value, new opportunities, or changes in market dynamics, making it an important factor to watch in the business landscape.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care

BURLINGTON, Mass. and JERUSALEM, July 20, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced a $3 million minority equity investment in Radial Health, Inc. (“Radial”), a management services organization supporting a leading network of Brain Medicine clinics across the country. The investment was made as part of Radial's previously-announced Series A financing, and BrainsWay joins other leading investors in Radial, including General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.

Radial specializes in the development of the clinical infrastructure, reimbursement tools, and AI-guided decision support platform designed to support the delivery of “Brain Medicine” treatments, non-invasive therapies like Deep TMS™ and other solutions. The financing is expected to support Radial’s exploration of various M&A opportunities.

“We are pleased to announce our strategic minority investment in Radial, a mental health services provider that is expanding access to advanced psychiatric care,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “This investment in Radial represents the continued execution of our strategic initiative to secure minority equity positions in high performing mental health provider networks that can help expand awareness of and broaden access to noninvasive mental health treatment.”

“This financing represents an important step forward for Radial as we continue building a national platform for advanced mental health care,” said John Capecelatro, CEO and co-founder of Radial. “We are grateful for the support of BrainsWay and our broader syndicate of investors as we use this capital to expand our clinical footprint, strengthen our technology platform and increase access to innovative, evidence-based Brain Medicine treatment options for patients.”

Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction as well as on the Company’s prior minority stake investments.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks relating to the Company’s ability to consummate, finance and close proposed or potential investments, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts: 
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Jeff Warren
LifeSci Advisors LLC
jwarren@lifesciadvisors.com

FAQ

What did BrainsWay (NASDAQ: BWAY) announce on July 20, 2026 regarding Radial Health?

BrainsWay announced a strategic minority equity investment of $3 million in Radial Health’s Series A round. According to BrainsWay, Radial supports a leading Brain Medicine clinic network, and the investment aligns with BrainsWay’s plan to expand access to advanced noninvasive mental health treatments.

How much did BrainsWay (BWAY) invest in Radial Health’s Series A financing?

BrainsWay invested $3 million as a minority equity stake in Radial Health’s Series A financing. According to BrainsWay, this positions the company alongside investors such as General Catalyst and others backing Radial’s national Brain Medicine platform and related clinical and technology infrastructure.

Why is BrainsWay investing in Radial Health and other mental health provider networks?

BrainsWay views minority investments in mental health provider networks as part of its strategic initiative. According to BrainsWay, these stakes can help raise awareness of Deep TMS and broaden access to noninvasive, evidence-based psychiatric treatments through high-performing clinical platforms like Radial Health.

What does Radial Health do in Brain Medicine and how is BrainsWay involved?

Radial Health develops clinical infrastructure, reimbursement tools and an AI-guided decision support platform for Brain Medicine clinics. According to BrainsWay, its $3 million minority investment supports Radial’s efforts to deliver noninvasive treatments such as Deep TMS and pursue various M&A opportunities.

How could BrainsWay’s BWAY investment in Radial Health affect access to mental health care?

The investment could support broader access to advanced mental health treatments by strengthening Radial’s platform. According to BrainsWay, partnering with a growing Brain Medicine network may help expand awareness and availability of noninvasive therapies, including Deep TMS, at clinics across the United States.

Who are the other investors alongside BrainsWay in Radial Health’s Series A round?

BrainsWay joins several institutional and venture investors in Radial Health’s Series A financing. According to BrainsWay, participants include General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital and Diede van Lamoen supporting Radial’s national Brain Medicine strategy.